Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
株式のランク #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
株価
$0.15
時価総額
$4.96M
変化(1日)
0.00%
変化(1年)
0.00%
CA
取引 Intellipharmaceutics International Inc. (IPCIF)

カテゴリー

Intellipharmaceutics International Inc.(IPCIF)のP/B比率
March 2026 時点のP/B比率 TTM: -0.47
Intellipharmaceutics International Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は -0.47 です。2021 年末時点でのP/B比率は -0.33 でした。
Intellipharmaceutics International Inc. の P/B 比率の履歴(1999 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) -0.47 113.32%
2022 -0.22 -34.41%
2021 -0.33 -11.10%
2020 -0.38 -26.74%
2019 -0.51 -233.83%
2018 0.38 -99.44%
2017 68.23 2.24%
2016 66.73 -118.41%
2015 -362.51 -2,780.81%
2014 13.52 -203.90%
2013 -13.01 -44.91%
2012 -23.62 55.20%
2011 -15.22 -104.91%
2010 309.77 0.00%
2009 0.00 -100.00%
2008 17.17 306.71%
2007 4.22 106.77%
2006 2.04 42.40%
2005 1.43 112.45%
2004 0.67 5.55%
2003 0.64 -23.08%
2002 0.83 -2.59%
2001 0.85 10.74%
2000 0.77 -62.55%
1999 2.06 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
5.6573 -1,305.48%
DK
6.3842 -1,460.37%
US
2.4551 -623.14%
US
4.364 -1,029.90%
BE
5.9034 -1,357.92%
NL